Notably, BCAT1 promotes BCAA production in BCR-ABL–driven chronic myelogenous leukemia, in which BCAT1 blockade impairs B cell proliferation and causes differentiation (77). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.